Results 81 to 90 of about 61,821 (357)

Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia [PDF]

, 2017
Acute Myeloid Leukaemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure.
Gibson, Brenda E.S., Harrison, Christine J., Keeshan, Karen, Laing, Alison A.   +3 more
core   +1 more source

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

Advanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, Wing Leung   +10 more
wiley   +1 more source

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

OncoImmunology, 2021
Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it.
Haiping Jiang, Haiqing Ni, Pan Zhang, Xiaoli Guo, Min Wu, Haoran Shen, Jie Wang, Weiwei Wu, Zhihai Wu, Jiazheng Ding, Rong Tang, Shuaixiang Zhou, Bingliang Chen, Michael Yu, Hua Jing, Junjian Liu   +15 more
doaj   +1 more source

Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy [PDF]

, 2020
Mesenchymal stem cells (MSCs) are among the most frequently used cell type for regenerative medicine. A large number of studies have shown the beneficial effects of MSC-based therapies to treat different pathologies, including neurological disorders ...
Capilla González, Vivian, Gauthier, Benoit R., Hmadcha, Abdelkrim, Martín Montalvo, Alejandro, Soria Escoms, Bernat   +4 more
core   +1 more source

Figure S9 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers [PDF]

, 2023
Divya Mathur, Adam R. Root, Bozena Bugaj‐Gaweda, Stephanie Bisulco, Xingzhi Tan, Wei Fang, Jessica Kearney, Justin Lucas, Magali Guffroy, Jonathan Golas, Cynthia M. Rohde, Chad Stevens, Cris Kamperschroer, Kerry Kelleher, Rosemary F. Lawrence-Henderson, Erik Upeslacis, Johnny Yao, Jatin Narula, Edward R. LaVallie, Diane R. Fernandez, Bernard S. Buetow, Edward Rosfjord, Laird Bloom, Lindsay E. King, Lioudmila Tchistiakova, Anhco Nguyen, Puja Sapra   +26 more
openalex   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs

Pharmaceutics
Background/Objectives: All current FDA-approved antibody–drug conjugates (ADCs) are single-target and single-payload molecules that have limited efficacy in patients due to drug resistance.
Nicole A. Wilski, Peter Haytko, Zhengxia Zha, Simin Wu, Ying Jin, Peng Chen, Chao Han, Mark L. Chiu   +7 more
doaj   +1 more source

Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors

Advanced Science, EarlyView.
This study reports the development of a fully humanized bispecific T cell engager targeting IL13RA2, a tumor‐associated antigen enriched in glioblastoma. This off‐the‐shelf immunotherapy drives potent, antigen‐dependent T cell activation and tumor killing, and prolongs survival in experimental GBM and other solid tumors models without detectable off ...
Joseph T. Duffy, Angela Martin‐Regalado, Benedikt E. Haupt, Jacob R. Pogue, Aditi Thakur, Manuel Fierro Cota, Markella Zannikou, Sol Misener, Vera P. Krymskaya, Kathleen McCortney, Jason Miska, Craig Horbinski, Dmitri Simberg, Maciej S. Lesniak, Charles D. James, Roger Stupp, Irina V. Balyasnikova   +16 more
wiley   +1 more source

AND‐Logic‐Gated Aptamer Switch for Precise Targeting and Regulation of RNA G‐Quadruplexes

Angewandte Chemie, EarlyView.
An AND‐logic‐gated aptamer switch enables tumor‐selective activation of RNA G‐quadruplex (rG4)‐targeting function. By combining cell‐surface recognition and intracellular redox sensing, the system achieves precise regulation of disease‐relevant RNA structures exclusively in tumor cells, with minimal off‐target effects in normal cells, offering a ...
Dan Wang, Ying Feng, Chun Kit Kwok
wiley   +2 more sources

Antibodies to watch in 2026

mAbs
The Antibodies to Watch article series provides annual updates on commercial late-stage clinical development, regulatory review, and marketing approvals of antibody therapeutics.
Silvia Crescioli, Hélène Kaplon, Alicia Chenoweth, Yu-Shin Hsu, Kieran Pinto, Vaishali Kapoor, Janice M. Reichert   +6 more
doaj   +1 more source